In re Metformin Settlement $26 Million for NDMA Marketing and Sales Claims

Metformin, a widely prescribed diabetes medication, came under scrutiny after regulators identified contamination by NDMA (N-nitrosodimethylamine), a chemical classified by U.S. health authorities as a probable human carcinogen. FDA updates and public communications described NDMA findings and related drug-safety actions, raising concerns for patients and others about the safety and handling of metformin products. In parallel, a class action in federal court focused not on contamination itself, but on allegations that marketing and sales practices connected to metformin misrepresented information to consumers and healthcare stakeholders, potentially influencing purchasing and prescribing decisions. The lawsuit—*In re Metformin Marketing and Sales Practices Litigation* (Civil Action No. 20-cv-02334-MCA-MAH in the U.S. District Court for the District of New Jersey)—was filed to address those alleged misstatements and omissions and to seek compensation for affected parties through a settlement. The $26 million resolution reflects the legal system’s broader role in balancing patient protection with accountability for how drug information is communicated; it also highlights why “how a drug is sold” can become as consequential as “what’s in a drug.” Claims were funneled through the settlement process at InReMetforminSettlement.com, underscoring the structured, court-supervised nature of class settlements. Broader implications extend to the pharmaceutical industry’s compliance obligations under FDA regulations governing drug labeling, advertising, and promotion—areas where misbranding or misleading promotional claims can trigger investigations and litigation. Similar cases in recent years have emerged whenever public-health risks intersect with alleged marketing failures, particularly involving contamination concerns, product safety communications, and the accuracy of information presented to patients and prescribers. Against this regulatory backdrop, the metformin settlement illustrates how enforcement and private litigation can work together to shape industry messaging practices and strengthen incentives for transparency when safety concerns arise.